<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Middle East Afr J Ophthalmol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Middle East Afr J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">MEAJO</journal-id>
      <journal-title-group>
        <journal-title>Middle East African Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0974-9233</issn>
      <issn pub-type="epub">0975-1599</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24339692</article-id>
      <article-id pub-id-type="pmc">3841960</article-id>
      <article-id pub-id-type="publisher-id">MEAJO-20-363</article-id>
      <article-id pub-id-type="doi">10.4103/0974-9233.120001</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Recurrent Central Serous Chorioretinopathy with Dexamethasone Eye Drop used Nasally for Rhinitis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Prakash</surname>
            <given-names>Gunjan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shephali</surname>
            <given-names>Jain</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tirupati</surname>
            <given-names>Nath</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ji</surname>
            <given-names>Pandey D</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Ophthalmology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India</aff>
      <aff id="aff2"><label>1</label>Department of Ophthalmology, Trinetra Medical Institute and Research Centre, Kamla Nagar, Agra, Uttar Pradesh, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Corresponding Author:</bold> Dr. Gunjan Prakash, B-2/22, Kamla Nagar, Agra, Uttar Pradesh, India. E-mail: <email xlink:href="gunjan_prakash@rediffmail.com">gunjan_prakash@rediffmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Oct-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>20</volume>
      <issue>4</issue>
      <fpage>363</fpage>
      <lpage>365</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Middle East African Journal of Ophthalmology</copyright-statement>
        <copyright-year>2013</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Central serous chorioretinopathy (CSC) is characterized by serous retinal detachment at the posterior pole. Several factors have been implicated in the pathogenesis, and endogenous or exogenous corticosteroids are thought to play a major role. Here we present a case of a 35-year-old male with complaints of a dark circle in front of his right eye. Fundus examination, optical coherence tomography and fundus fluorescein angiography were performed. The patient was diagnosed with CSC. CSC resolved completely within seven weeks. Four weeks later the CSC recurred and spontaneously resolved over eight weeks. Overall, the patient had three additional recurrences of CSC in the same eye over the next year. A detailed history taking revealed the patient was using 0.1% dexamethasone eye drops nasally for recurrent rhinitis for few days prior to each episode of CSC. This indicates the strong correlation between steroids given by any route and the pathogenesis of CSC.</p>
      </abstract>
      <kwd-group>
        <kwd>Central Serous Chorioretinopathy</kwd>
        <kwd>Cortisol</kwd>
        <kwd>Dexamethasone</kwd>
        <kwd>Nasal Drop</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-1">
      <title>INTRODUCTION</title>
      <p>Central serous chorioretinopathy (CSC) is a focal retinal detachment due to fluid accumulation underneath the sensory retina. Endogenous and exogenous corticosteroids has been implicated in the pathogenesis of CSC.[<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref>] This case report presents the development of CSC after the use of dexamethasone eye drops as a nasal drop. To our knowledge one case series and a case report is documented in literature, which specifically linked CSC with use of intranasal steroids.[<xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref4">4</xref>] In the previous publications, fluticasone or beclomethasone were used.[<xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref4">4</xref>] This is the first case described in literature, suggestive of CSC due to nasal use of dexamethasone drops for rhinitis.</p>
    </sec>
    <sec id="sec1-2">
      <title>CASE REPORT</title>
      <p>A 35-year-old male, optometrist by profession, visited our hospital with complaint of seeing a dark circle in front of his right eye with onset three days prior to presentation. Patient was a non-smoker, non-alcoholic, non-hypertensive, was not on any medication and followed a healthy life style. Vision was 6/18 in the right eye with best corrected visual acuity (BCVA) of 6/6 with +2.0 D sphere. Anterior segment and intraocular pressure were normal. Fundus examination showed a bleb like elevation of retina. Fundus fluorescein angiography (FFA) showed ink blot leakage [<xref ref-type="fig" rid="F1">Figure 1</xref>]. Coherence tomography (OCT) is shown in <xref ref-type="fig" rid="F2">Figure 2a</xref>. The patient was diagnosed with CSC. The patient was prescribed 0.5% carboxymethylcellulose eye drops thrice a day and asked to return for follow up every two weeks. CSC completely resolved, clinically and on OCT, within seven weeks [<xref ref-type="fig" rid="F2">Figure 2b</xref>]. Four weeks later the patient had a recurrence that again resolved spontaneously over eight weeks. In all, patient had three additional episodes of CSC in the same eye over the next year [<xref ref-type="fig" rid="F3">Figure 3</xref>]. Each time patient denied any form of corticosteroid use. After detailed questioning, he admitted, that he used dexamethasone eye drops, nasally for five to seven days before each episodes. This suggests the strong correlation between steroids given by any route and pathogenesis of CSC. This is also first case ever of confirmed CSC due to nasal intake of steroid drops.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>(a) Fundus photograph showing a fluid-filled bleb-like elevation at the posterior pole Figure (b), (c) and (d): Showing small hyperfluorescence spot in early phase, which gradually increased in size due to leakage taking an ink blot pattern</p>
        </caption>
        <graphic xlink:href="MEAJO-20-363-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>(a) OCT shows area of detachment as hyporeflectivity between neurosensory retina and RPE (b) Shows flattening of retinal contour after seven weeks</p>
        </caption>
        <graphic xlink:href="MEAJO-20-363-g002"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>OCT showing serous retinal detachment at first and second recurrence</p>
        </caption>
        <graphic xlink:href="MEAJO-20-363-g003"/>
      </fig>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>DISCUSSION</title>
      <p>Emotional liability, neuroticism and introversion, hysteria, type A personality, pregnancy, have been suggested to predispose to CSC. Symptoms include sudden blurring of vision, central and paracentral scotoma, micropsia, macropsia. Von Graefe was the first to describe CSC. He called it recurrent central retinitis.[<xref ref-type="bibr" rid="ref5">5</xref>] CSC is a serous detachment of the retina due to serum leakage from the choroidal circulation through a break in the diffusion barrier, made of tight junction around the retinal pigment epithelial (RPE) cells. The proposed pathogenesis is that steroid use leads to reduced absorption of subretinal fluid by altering the permeability of choriocapillaris and ion transport mechanism at the mineralocorticoid level.[<xref ref-type="bibr" rid="ref6">6</xref><xref ref-type="bibr" rid="ref7">7</xref>] Carvallo-Recchia <italic>et al</italic>. were the first to report a statistically significant relation between exogenous corticosteroid use and CSC.[<xref ref-type="bibr" rid="ref8">8</xref>] Multiple reports have suggested the development of CSC after the use of steroids in any form.[<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref10">10</xref>] To our knowledge one case series and a case report is documented in the literature which specifically links CSC with use of intranasal steroids.[<xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref4">4</xref>] Intranasal corticosteroids are widely used for allergic rhinitis and it is often purchased as over-the-counter drug. A position paper by joint task force for the American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma and Immunology stated that, &#x201C;data suggest that the use of inhaled corticosteroids is associated with an increased risk of adverse ocular effects and that the risk increases with dose and duration of therapy,&#x201D; leading them to recommend that intranasal corticosteroids not be approved for over-the-counter use.[<xref ref-type="bibr" rid="ref11">11</xref>] Any patient using steroid in any form must be informed about the possibility of development of CSC and should immediately report to a treating doctor and ophthalmologist on the appearance of symptoms, and the drug should be discontinued. This is the first case in the literature, suggestive of CSC after use of dexamethasone eye drop in the form of nasal drop for recurrent allergic rhinitis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> None declared.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haimovici</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gagnon</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Lehrfeld</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wellik</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Central serous chorioretinopathy case-control study group. Risk factors for central serous chorioretinopathy: A case-control study</article-title>
          <source>Ophthalmology</source>
          <year>2004</year>
          <volume>111</volume>
          <fpage>244</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">15019370</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karadimas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kapetanios</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bouzas</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Central serous chorioretinopathy after local application of glucocorticoids for skin disorders</article-title>
          <source>Arch Ophthalmol</source>
          <year>2004</year>
          <volume>122</volume>
          <fpage>784</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">15136332</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haimovici</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gragoudas</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Duker</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Sjaarda</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Eliott</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids</article-title>
          <source>Ophthalmlogy</source>
          <year>1997</year>
          <volume>104</volume>
          <fpage>1653</fpage>
          <lpage>60</lpage>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleinberger</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lieberman</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Malnik</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Bilateral central serous chorioretinopathy caused by intranasal corticosteroids: A case report and review of the literature</article-title>
          <source>Laryngoscope</source>
          <year>2011</year>
          <volume>121</volume>
          <fpage>2034</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">22024860</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Von Graefe</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Ueber central recidivierende retinitis</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>1866</year>
          <volume>12</volume>
          <fpage>211</fpage>
          <lpage>5</lpage>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arndt</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Sari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parrat</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Courtas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>De Seze</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Electrophysiological effects of corticosteroids on retinal pigment epithelium</article-title>
          <source>Invest Ophthalmol Vis Sci</source>
          <year>2001</year>
          <volume>42</volume>
          <fpage>472</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">11157885</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bouzas</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Mastorakos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chrousos</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Kaiser-Kupfer</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
          <article-title>Central serous chorioretinopathy in endogenous hypercortisolism</article-title>
          <source>Arch Ophthalmol</source>
          <year>1993</year>
          <volume>111</volume>
          <fpage>1229</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">8363466</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavalho-Recchia</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Yannuzzi</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Negr&#xE3;o</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Spaide</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Freund</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Rodriguez-Coleman</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Corticosteroid and central serous chorioretinopathy</article-title>
          <source>Ophthalmology</source>
          <year>2002</year>
          <volume>109</volume>
          <fpage>1834</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">12359603</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bevis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ratnakaram</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Bhatti</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Visual loss due to central serous chorioretinopathy during corticosteroid treatment for giant cell arteritis</article-title>
          <source>Clin Experiment Ophthalmol</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>437</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">16033370</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marcus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Belfair</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Klemperer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lifshitz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Central serous chorioretinopathy in patients receiving systemic corticosteroid therapy</article-title>
          <source>Can J Ophthalmol</source>
          <year>2005</year>
          <volume>40</volume>
          <fpage>217</fpage>
          <lpage>21</lpage>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bielory</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Blaiss</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fineman</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Ledford</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Lieberman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Simons</surname>
              <given-names>FE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Concerns about intranasal corticosteroids for over-the-counter use: Positon statement of Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2006</year>
          <volume>96</volume>
          <fpage>514</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">16680921</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
